Acromegaly Update - Ethan Weiss

Podcast details

Technical and general information from the podcast's RSS feed.

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

Publication history

Monthly episode publishing history over the past years.

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Acromegaly Update — Monday July 27, 2026

Monday, July 27, 2026 • Duration 07:00

A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing startup inked a licensing deal and orphan drugmakers pushed back on Medicare price-pilot exposure.

Read moreCollapse

Acromegaly Update — Monday July 20, 2026

Monday, July 20, 2026 • Duration 07:00

A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.

Read moreCollapse

Acromegaly Update — Monday July 13, 2026

Monday, July 13, 2026 • Duration 04:09

It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

Read moreCollapse

Acromegaly Update — Monday July 6, 2026

Monday, July 6, 2026 • Duration 07:23

It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

Read moreCollapse

Acromegaly Update — Monday June 29, 2026

Monday, June 29, 2026 • Duration 07:00

Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

Read moreCollapse

Acromegaly Update — Monday June 22, 2026

Monday, June 22, 2026 • Duration 12:00

A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

Read moreCollapse

Acromegaly Update — Monday June 15, 2026

Monday, June 15, 2026 • Duration 07:00

Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

Read moreCollapse

Acromegaly Update — Monday June 8, 2026

Monday, June 8, 2026 • Duration 13:00

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.

Read moreCollapse

Acromegaly Update — Monday June 1, 2026

Monday, June 1, 2026 • Duration 07:00

New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

Read moreCollapse

Acromegaly Update — Monday May 25, 2026

Monday, May 25, 2026 • Duration 07:00

A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

Read moreCollapse

Acromegaly Update – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Acromegaly Update – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify